Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease

BMC Immunology

Ming-hui Zhao¹  Zhao Cui²  Feng Yu²  Xiao-wei Yang²  Xiao-yu Jia²  Shui-yi Hu² 

[1] Peking-Tsinghua Center for Life Sciences, Beijing, China;Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease, Prevention and Treatment, Ministry of Education, Beijing, China

关键词: Anti-C1q antibody;    C1q;    Classical pathway;    Complement;    Anti-glomerular basement membrane disease;   

Others  :  1077759
DOI  :  10.1186/1471-2172-14-42

 received in 2013-05-03, accepted in 2013-09-11,  发布年份 2013

【 摘 要 】

Background

Anti-glomerular basement membrane (GBM) disease is a well-known antibody-induced autoimmune disease. A few patients have glomerular C1q deposition, but it is usually absent on renal histopathology. The role of C1q deposition in kidney injury is unclear. Recently, anti-C1q antibodies are demonstrated to be pathogenic in the target organ damage of many autoimmune diseases, by facilitating C1q deposition and enhancing complement activation via classical pathway. In the current study, we investigated the associations between anti-C1q antibodies in sera and C1q deposition in kidney of patients with anti-GBM disease.

Results

It was shown that the severity of kidney injury was comparable between patients with and without C1q deposition, including the prevalence of oliguria/auria, the median percentage of crescents in glomeruli and the mean concentration of serum creatinine. Serum anti-C1q antibodies were detected in 15/25 (60%) patients with a low titer. The prevalence of C1q deposition in kidney was comparable between patients with and without serum anti-C1q antibodies (26.7% vs. 30.0%, p > 0.05). No association was found between anti-C1q antibodies and the severity of kidney injury.

Conclusions

The classical pathway of complement may not play a pathogenic role in the kidney injury of human anti-GBM disease. Anti-C1q antibodies could be detected in more than half of patients, which need further investigations.

【 授权许可】

   
2013 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lerner RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967, 126:989-1004.
• [2]Wilson CB, Dixon FJ: Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3:74-89.
• [3]Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med 2003, 348:2543-2556.
• [4]Fischer EG, Lager DJ: Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol 2006, 125:445-450.
• [5]Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH: Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110:403-409.
• [6]Otten MA, Groeneveld TW, Flierman R, et al.: Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol 2009, 183:3980-3988.
• [7]Robson MG, Cook HT, Botto M, et al.: Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001, 11:6820-6828.
• [8]Ma R, Cui Z, Liao YH, Zhao MH: Complement Activation Contributes to the Injury and Outcome of Kidney in Human Anti-glomerular Basement Membrane Disease. J Clin Immunol 2013, 33:172-178.
• [9]Uwatoko S, Aotsuka S, Okawa M, et al.: Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol 1984, 30:104-116.
• [10]Kozyro I, Korosteleva L, Chernoshej D, Danner D, Sukalo A, Trendelenburg M: Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol 2008, 128:409-414.
• [11]Potlukova E, Jiskra J, Limanova Z, et al.: Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin Exp Immunol 2008, 153:96-101.
• [12]Siegert CE, Daha MR, Halma C, van der Voort EA, Breedveld FC: IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992, l10:19-23.
• [13]Coremans IE, Daha MR, van der Voort EA, Muizert Y, Halma C, Breedveld FC: Antibodies against C1q in anti-glomerular basement membrane nephritis. Clin Exp Immunol 1992, 87:256-260.
• [14]Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR: Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 2003, 132:32-39.
• [15]Trouw L, Duijs J, Van Kooten C, Daha M: Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. Mol Immunol 2003, 40:595-602.
• [16]Trouw LA, Groeneveld TWL, Seelen MA, et al.: Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004, 114:679-688.
• [17]Feith GW, Assmann KJ, Bogman MJ, et al.: Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice. Nephrol Dial Transplant 1996, 11:599-607.
• [18]Thurman JM, Holers VM: The central role of the alternative complement pathway in human disease. J Immunol 2006, 176:1305-1310.
• [19]Lachmann PJ: The amplification loop of the complement pathways. Adv Immunol 2009, 104:115-149.
• [20]Harboe M, Mollnes TE: The alternative complement pathway revisited. J Cell Mol Med 2008, 12:1074-1084.
• [21]Chen PC, Wang CR, Liu MF, et al.: Correlation between the renal C1q deposition and serum anti-C1q antibody: a potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol 2002, 20:223-227.
• [22]Marto N, Bertolaccini ML, Calabuig E, et al.: Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:444-448.
• [23]Akhter E, Burlingame RW, Seaman AL, et al.: Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011, 20:1267-1274.
• [24]Daha M: Possible mechanisms of degradation of C1q in vivo and in vitro: role of macrophages. Behring Inst Mitt 1989, 84:42-46.
• [25]Katsumata Y, Miyake K, Kawaguchi YH, et al.: Anti-C1q Antibodies Are Associated With Systemic Lupus Erythematosus Global Activity but Not Specifically With Nephritis. Arthritis Rheum 2011, 63:2436-2444.
• [26]Wener MH, Uwatoko S, Mannik M: Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 1989, 32:544-551.